menu
    • menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Drugs for Neglected Diseases","sponsor":"Bayer AG | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drugs for Neglected Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Drugs for Neglected Diseases \/ Bayer AG | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Drugs for Neglected Diseases \/ Bayer AG | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Drugs for Neglected Diseases","sponsor":"Bayer AG | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Drugs for Neglected Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Drugs for Neglected Diseases \/ Bayer AG | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Drugs for Neglected Diseases \/ Bayer AG | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Drugs for Neglected Diseases","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Drugs for Neglected Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Drugs for Neglected Diseases \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Drugs for Neglected Diseases \/ Bayer AG"},{"orgOrder":0,"company":"Swiss Tropical and Public Health Institute","sponsor":"Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swiss Tropical and Public Health Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Tropical and Public Health Institute \/ Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation","highestDevelopmentStatusID":"10","companyTruncated":"Swiss Tropical and Public Health Institute \/ Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation"},{"orgOrder":0,"company":"Swiss Tropical and Public Health Institute","sponsor":"Bayer AG | Silicon Valley Community Foundation | University of the Philippines","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Swiss Tropical and Public Health Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swiss Tropical and Public Health Institute \/ Bayer AG | Silicon Valley Community Foundation | University of the Philippines","highestDevelopmentStatusID":"10","companyTruncated":"Swiss Tropical and Public Health Institute \/ Bayer AG | Silicon Valley Community Foundation | University of the Philippines"},{"orgOrder":0,"company":"Drugs for Neglected Diseases","sponsor":"Bayer AG | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Drugs for Neglected Diseases","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Drugs for Neglected Diseases \/ Bayer AG | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Drugs for Neglected Diseases \/ Bayer AG | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Swiss TPH","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2023","type":"Partnership","leadProduct":"Emodepside","moa":"Gqalpha protein\/Phospholipase-Cbeta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Swiss TPH","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Swiss TPH"}]

    Find Clinical Drug Pipeline Developments & Deals for Emodepside

    Menu

    Emodepside

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Swiss Tropical and Public Health Institute

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Swiss Tropical and Public Health Institute

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Bayer AG | Silicon Valley Community Foundation | University of the Philippines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections

                            Details : Emodepside is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Trichuriasis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 29, 2025

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Bayer AG | Silicon Valley Community Foundation | University of the Philippines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Swiss Tropical and Public Health Institute

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Swiss Tropical and Public Health Institute

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections

                            Details : Emodepside is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Trichuriasis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Public Health Laboratory Ivo de Carneri | Bayer AG | Silicon Valley Community Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bayer AG

                            Germany arrow
                            Florida Innovation
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When...

                            Details : BAY 44-4400 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Helminthiasis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 14, 2024

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bayer AG

                            Germany arrow
                            Florida Innovation
                            Not Confirmed

                            Bayer AG

                            Germany arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Swiss TPH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Bayer and Swiss TPH to Develop Treatment Against Soil-Transmitted Helminths

                            Details : The partnership aims to jointly develop emodepside, an anthelmintic substance that is effective against several gastrointestinal nematodes in domestic animals, in the clinical development for treating humans infected with soil-transmitted helminths.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Swiss TPH

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emodepside Phase II Trial for Treatment of Onchocerciasis

                            Details : Emodepside is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Onchocerciasis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 06, 2022

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Relative Bioavailability Study of Emodepside IR-tablets and Solution

                            Details : Emodepside is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Filariasis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 26, 2017

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside

                            Details : Emodepside is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Filariasis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            December 26, 2017

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            Drugs for Neglected Diseases

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Man Clinical Trial of Emodepside (BAY 44-4400)

                            Details : Emodepside is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            January 22, 2016

                            Lead Product(s) : Emodepside

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Bayer AG | Bill & Melinda Gates Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth